Land: Bretland
Tungumál: enska
Heimild: MHRA (Medicines & Healthcare Products Regulatory Agency)
Formoterol fumarate dihydrate; Beclometasone dipropionate
Chiesi Ltd
R03AK08
Formoterol fumarate dihydrate; Beclometasone dipropionate
6microgram/1dose ; 100microgram/1dose
Pressurised inhalation
Inhalation
No Controlled Drug Status
Valid as a prescribable product
BNF: 03020000; GTIN: 5028613002797
DRAFT 1 (Mac - IDcc) 06/04/2018 CARATTERE/FONT: Arial CORPO/SIZE: 10pt (5) COD. SOST./REPLACES CODE: 0108002474/01 LINEA CONFEZIONAMENTO/ PACKAGING LINE: SPRAY CHIESI FARMACEUTICI S.P.A. - PARMA - ITALIA VIETATA LA MANOMISSIONE D.Q.O.C. UG - AUTORE/ARTWORKS LAB.: MS MAIL: M.SIGURANI@CHIESI.COM (1) DESCRIZIONE MATERIALE /DESCRIPTION OF MATERIAL DIMENSIONI/DIMENSIONS 540 x 300 mm (4) CODICE/ CHIESI FARMACEUTICI ITEM 0108003833/01 (2) F.TO A.A./FORMAT F065 (3) N° PHARMACODE 669 (cod. barre) DATAMATRIX: / DIMENSIONI PIEGATO/ AFTER FOLDING 180 x 38 mm COLORI DI STAMPA/COLOURS PRINT: N. 1 FUSTELLA/ DIE F.E.FOSTAIR 100/6MCG 120D MDI DC CH LTD (7) RIF. RICH. DI CODIFICA DEL /REFERS TO NEW CODE REQUEST OF 05/04/2018- (6) MOTIVO/REASON: - Regolatorio/REGULATORY MODIFICATION: TYPE II VARIATION FOR TEXT HARMONISATION, CHANGE ON PIL - Tecnico/TECHNICAL MODIFICATION: UPDATED LAETUS AND CHIESI FARMACEUTICI ITEM PRODUCTION LINE: BLOIS SITE AND PARMA SITE NOTE PER IL FORNITORE/NOTE FOR SUPPLIER: TOT. PAG. PDF: N.2 LINGUA/LANGUAGE: ENGLISH BLACK+ halftones TECHNICAL INFORMATION / INFORMAZIONI TECNICHE DEFINITIVO: X PDF per il fornitore e Chiesi Farmaceutici / FINAL PRINT: X PDF FOR SUPPLIER AND CHIESI FARMACEUTICI PAG. 1/2 0108003833/01 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk with your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. WHAT FOSTAIR IS AND WHAT IT IS USED FOR. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE FOSTAIR 3. HOW TO USE FOSTAIR 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE FOSTAIR 6. CONTENT OF THE PACK AND OTHER INFORMATION 1. WHAT FOSTAIR IS AND WH Lestu allt skjalið
OBJECT 1 FOSTAIR 100/6 INHALATION SOLUTION Summary of Product Characteristics Updated 16-Apr-2018 | Chiesi Limited 1. Name of the medicinal product Fostair 100/6 micrograms per actuation pressurised inhalation solution. 2. Qualitative and quantitative composition Each metered dose (ex-valve) contains: 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of 84.6 micrograms of beclometasone dipropionate and 5.0 micrograms of formoterol fumarate dihydrate. For the full list of excipients see section 6.1. 3. Pharmaceutical form Pressurised inhalation, solution. Colourless to yellowish solution. 4. Clinical particulars 4.1 Therapeutic indications Asthma Fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta 2 -agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta 2 -agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta 2 -agonists. COPD Symptomatic treatment of patients with severe COPD (FEV 1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. 4.2 Posology and method of administration FOSTAIR is for inhalation use. POSOLOGY ASTHMA FOSTAIR is not intended for the initial management of asthma. The dosage of the components of Fostair is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of beta 2 -agonists and/or corticosteroids by individual inhalers should be prescribed. Beclometasone dipropionate in Fostair is characterised by an extrafine partic Lestu allt skjalið